Dosing reference
Every dose that has been studied in humans
Label dosing for approved drugs, the amounts given in registered trials of investigational drugs, and a plain “none established” everywhere else. No forum numbers, no vendor charts. Every figure cites its source.
22 · FDA label15 · Trial doses71 · None established
Reconstitution guide
Lab steps with photos, syringe units and storage.
How long studies ran
Cycle-length evidence: treatment and follow-up durations.
Combinations
What is actually studied when compounds are paired.
Human dosing quick-reference chart
Click any compound for the cited dosing page, study durations and vial arithmetic.
| Compound | Research area | Status | Human amounts | Route studied | Half-life | Evidence | |
|---|---|---|---|---|---|---|---|
| ARA-290 | Recovery & Repair | Investigational | 1 mg, 4 mg and 8 mg per day subcutaneously in phase 2 trials; 2 mg intravenously three times weekly in the 2012 sarcoidosis pilot; single 2 mg intravenous dose in a healthy-volunteer study | Subcutaneous in the phase 2 neuropathy, diabetes and macular oedema trials; intravenous in the sarcoidosis pilot and the healthy-volunteer emotional-processing study | — | B | View |
| B7-33 | Recovery & Repair | Not approved | None established | — | — | C | View |
| BPC-157 | Recovery & Repair | Not approved | None established | Human reports describe intra-articular injection, injection into the bladder wall at cystoscopy, intravenous infusion and oral administration | — | C | View |
| Pentadeca arginate (PDA) | Recovery & Repair | Not approved | None established | — | — | — | View |
| TB-500 | Recovery & Repair | Not approved | None established | Published human studies used full-length thymosin beta-4, given as ophthalmic solution, topical gel, intravenous infusion or intravenous recombinant protein | — | C | View |
| Thymosin beta-4 | Recovery & Repair | Investigational | 0.1% RGN-259 eye drop in SEER-1 and dry-eye trials; intravenous synthetic Tβ4 42-1260 mg in a phase 1 healthy-volunteer study | Topical ophthalmic (RGN-259); intravenous (phase 1 and myocardial infarction studies) | Not reported numerically in the sources reviewed; rose with dose in phase 1 | B | View |
“Human amounts” is a summary; the dosing page for each compound carries the full cited statements. Compounds approved nowhere show “None established” by policy, whatever is circulated elsewhere. Why.
What every dosing page includes
- Quick-reference card
- Label or trial doses, cited
- How long studies ran
- Who was excluded
- Side effects reported
- Reconstitution arithmetic + syringe chart
- Supplies, storage and handling mistakes
- Regulatory status
- Comparison with related compounds
- Combinations and FAQs
Don’t see a compound?
Tell us what to research next. We add compounds when there are primary sources to cite.